ENDOcare plans 1997 trial for urinary stent:
This article was originally published in Clinica
ENDOcare says it plans to start trials of its nitinol urinary stent in 1997. The stent is designed for temporary relief of obstructions. ENDOcare says stenting overcomes the limitations that urinary catheters place on the lifestyle of those who use them, while the shape-memory properties of the nitinol alloy will reduce the trauma of removal.
You may also be interested in...
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
The FDA has released final guidance on “Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA” for the industry. The guidance brings clarity and aims at facilitating product development meetings between the FDA and the ANDA applicants for complex products.
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.